- Home
- USIO vs IMA Comparison
USIO vs IMA Comparison
Compare USIO & IMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | USIO | IMA |
|---|---|---|
| Founded | 1998 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Bankers/Brokers/Service | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 58.8M | 66.3M |
| IPO Year | 1999 | 2021 |
Fundamental Metrics
Financial Performance| Metric | USIO | IMA |
|---|---|---|
| Price | $2.35 | $4.72 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 1 | 2 |
| Target Price | $4.00 | ★ $16.00 |
| AVG Volume (30 Days) | ★ 282.4K | 13.6K |
| Earning Date | 05-13-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.01 | N/A |
| Revenue | ★ $28,200,535.00 | $800,000.00 |
| Revenue This Year | $12.15 | N/A |
| Revenue Next Year | $8.57 | N/A |
| P/E Ratio | $228.00 | ★ N/A |
| Revenue Growth | ★ 12.69 | N/A |
| 52 Week Low | $1.03 | $3.94 |
| 52 Week High | $3.06 | $9.10 |
Technical Indicators
Market Signals| Indicator | USIO | IMA |
|---|---|---|
| Relative Strength Index (RSI) | 44.58 | 34.65 |
| Support Level | $2.15 | $4.69 |
| Resistance Level | $2.61 | $6.13 |
| Average True Range (ATR) | 0.16 | 0.31 |
| MACD | -0.03 | -0.00 |
| Stochastic Oscillator | 25.90 | 10.67 |
Price Performance
Historical ComparisonAbout USIO Usio Inc.
Usio Inc is a cloud-based Fintech payment processor. The company serves multiple industry verticals with technology that facilitates payment acceptance and funds disbursement in a single, full-stack ecosystem. It provides payment acceptance through multiple payment methods, including payment facilitation, prepaid card, and electronic billing products and services to businesses, merchants, and consumers. The company's reportable operating segments are Output Solutions and Merchant Services, and these segments.
About IMA ImageneBio Inc.
ImageneBio Inc is a clinical-stage biopharmaceutical company developing therapeutics for patients with immunological, autoimmune and inflammatory diseases. The company's flagship asset, IMG-007, is a non-depleting anti-OX40 monoclonal antibody that binds specifically to OX40 receptor on activated T cells to block receptor binding to OX40 ligand (OX40L). IMG-007 is being developed to potentially treat multiple autoimmune and inflammatory diseases and disorders. The company operates in a single segment.